Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Drospirenone Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne

NCT00656981
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
22
States / cities
Mobile, Alabama • Kingman, Arizona • Encino, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 24, 2026, 9:46 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

NCT03126097
View directory record Official record
Conditions
Healthy
Interventions
JNJ-64155806 150 mg, Ethinylestradiol/drospirenone 0.02 mg/3 mg, COCP Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

NCT01182194
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills

NCT03418363
View directory record Official record
Conditions
Contraceptive Usage, Coagulation
Interventions
DHEA Oral Capsule, Placebo Oral Capsule
Dietary Supplement · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

NCT00651469
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants

NCT02885454
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/ethinylestradiol, AL-335, Odalasvir (ODV), Simeprevir (SMV)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

NCT00567164
View directory record Official record
Conditions
Contraception, Ovulation Inhibition, Contraceptives, Oral
Interventions
EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,887 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
85
States / cities
Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Progestin-Only Pill Use and Breastfeeding Study

NCT04965116
View directory record Official record
Conditions
Contraception, Breastfeeding
Interventions
Progestin Only Contraceptive Pills
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 24, 2026, 9:46 AM EDT
Not yet recruiting Phase 4 Interventional

A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia

NCT07293728
View directory record Official record
Conditions
Hypertension, Preeclampsia
Interventions
Norethindrone 0.35 MG, Drospirenone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

NCT06820307
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine, DRSP/EE, NGM/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuous Versus Cyclical OCP Use in PCOS

NCT03819140
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Yasmin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

NCT07074327
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 24, 2026, 9:46 AM EDT
Terminated Phase 2 Interventional Results available

Binge Eating & Birth Control

NCT04278755
View directory record Official record
Conditions
Bulimia Nervosa, Binge Eating, Eating Disorders, Binge-Eating Disorder
Interventions
Drospirenone-Ethinyl Estradiol Oral Tablet
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function

NCT01109979
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Estradiol+MPA, Estradiol+Drospirenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 24, 2026, 9:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

NCT02269241
View directory record Official record
Conditions
Contraception
Interventions
LF111 (drospirenone)
Drug
Lead sponsor
Laboratories Leon Farma, S.A.
Industry
Eligibility
15 Years and older · Female only
Enrollment
1,552 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Anaheim, California • Costa Mesa, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 24, 2026, 9:46 AM EDT